Skip to main content
. Author manuscript; available in PMC: 2014 Jul 22.
Published in final edited form as: Cancer Cell. 2010 Dec 9;18(6):553–567. doi: 10.1016/j.ccr.2010.11.015

Table 1.

Clinical and Genetic Parameters of IDH1/2- and TET2-wild-type and mutant AML samples from the ECOG E1900 Cohort.

IDH & TET2
status		 Median Age
(Range)		 Gender
(M/F)		 Cytogenetic Risk Class
(Favorable/Intermediate/
Unfavorable/ Indeterminate)		 % FLT-3
mutant
(ITD/TKD)		 NPM1-
mutant
(%)		 CEBPA
mutant
(%)		 % bone marrow
blast at sample
acquisition
Median (range)
TET2 and
IDH1/2 Wildtype
(n=300)		 45.5 (18–60) 160/140 61/133/51/55 32%/8% 11% 11% 65% (3–100)
TET2 mutant
(n=28)		 55 (30–60) 17/11 2/10/4/12 35.7%/3.6% 21.4% 10.7% 69.5% (20–99)
IDH1 or 2
mutant (n=57)		 46.5 (18–60) 25/32 1/35/5/15 19.3%/3.5% 24.6% 1.8% 79% (11–100)
IDH1 mutant
(n=24)		 46 (18–58) 10/14 1/18/0/5 16.7%/0% 25% 4.2% 79% (30–96)
IDH2 mutant
(n=33)		 46.5 (24–60) 15/18 0/18/5/10 21.2%/6.1% 24.2% 0% 78% (11–100)
All patients
(n=385)		 46.5 (18–60) 202/183 64/179/60/82 31.7%/7% 14% 9.9% 68% (3–100%)